Table 1.

Published clinical trials evaluating fixed-combination brinzolamide and brimonidine

	Patients (n)	Dosage and duration	Change in intraocular pressure (mmHg) from baseline
			BBFC	Brinzolamide	Brimonidine
Nguyen et al23	n=679	3 times daily for 3 months	5.4–8.4	4.2–5.7	3.1–6.5
	1:1:1
	1) BBFC (n=218)
	2) brinzolamide 1% (n=229)
	3) brimonidine 0.2% (n=232)
Whitson et al24,*	n=679	3 times daily for 6 months	5.4–8.4	4.2–5.7	3.1–6.5
	1:1:1
	1) BBFC (n=218)
	2) brinzolamide 1% (n=229)
	3) brimonidine 0.2% (n=232)
Katz et al25	n=649	3 times daily for 3 months	7.1–8.8	4.3–6.2	3.5–5.8
	1:1:1
	1) BBFC (n=209)
	2) brinzolamide 1% (n=224)
	3) brimonidine 0.2% (n=216)
Realini et al26,#	n=1,350	3 times daily for 3 months	5.5–8.9	4.2–5.9	3.3–6.9
	1:1:1
	1) BBFC (n=437)
	2) brinzolamide 1% (n=458)
	3) brimonidine 0.2% (n=455)
Aung et al27	n=559	2 times daily for 6 months	7.2–9.3	5.5–7.2	5.2–8.1
	1:1:1
	1) BBFC (n=193)
	2) brinzolamide 1% (n=192)
	3) brimonidine 0.2% (n=175)
Gandolfi et al28	n=890	2 times daily for 6 months	7.3–9.3	7.7–9.4
	1:1
	1) BBFC (n=451)
	2) brinzolamide 1% plus
	brimonidine 0.2% (n=439)

Notes:

^*Three-month extension of Nguyen et al;²³

^#pooled data of Nguyen et al²³ and Katz et al.²⁵

Abbreviation: BBFC, brinzolamide 1% and brimonidine 0.2% fixed combination.